Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center

Kagawa, Kazufumi; Murakami, Masao; Hishikawa, Yoshio; Abe, Mitsuyuki; Akagi, Takashi; Yanou, Toshihiro; Kagiya, Gou; Furusawa, Yoshiya; Andō, Kōichi; Nojima, Kumie; Aoki, Mizuho; Kanai, Tatsuaki

doi:10.1016/s0360-3016(02)02949-8

Cited by 122 publications

(67 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,19,[25][26][27] However, carbon-ion therapy is more efficient against hypoxic tumor cells than x-ray radiation. The biological effects of proton irradiation have not been completely clarified, and many clinicians think that the clinical RBE of proton irradiation is higher than 1.1.…”

Section: Discussionmentioning

confidence: 99%

“…Results on carbon-ion therapy have only been reported from the National Institute of Radiological Sciences in Chiba, Japan. 19,32 The group has been investigating various fractionation schedules (from 18 to only 1 fraction, recently). We adopted their 4-fraction protocol, and have observed favorable outcome.…”

Section: Discussionmentioning

confidence: 99%

“…Biological effects of both proton therapy and carbon-ion therapy at the Hyogo Ion Beam Medical Center were evaluated in vitro and in vivo, and the relative biologic effectiveness (RBE) values for proton and carbon-ion irradiation at the Hyogo Ion Beam Medical Center were determined to be 1.1 and 2-3.7 (depending on the depth in the spread-out Bragg peaks), respectively. 19 Because all tissues are assumed to have almost the same RBE for proton or carbon ions, doses expressed in GyE are directly comparable to photon doses.…”

Section: Treatment Protocolsmentioning

confidence: 99%

See 2 more Smart Citations

High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancer

Iwata

Murakami

Demizu

et al. 2010

Cancer

Self Cite

100

View full text Add to dashboard Cite

patients with stage I NSCLC were treated with proton therapy or carbon-ion therapy (57 with proton therapy and 23 with carbon-ion therapy) using 3 treatment protocols. In the first protocol, 80 gray equivalents (GyE) of proton therapy was given in 20 fractions, and the second proton therapy protocol used 60 GyE in 10 fractions. For carbon-ion therapy, 52.8 GyE was given in 4 fractions. After achieving promising preliminary results for the first protocol, the authors started to use the second proton therapy protocol to shorten the overall treatment time. Carbon-ion therapy was started in 2005, and thereafter, both proton and carbon-ion therapy plans were made for each patient, and the 1 that appeared superior was adopted. Patient age ranged from 48 to 89 years (median, 76 years). Thirty-seven patients were medically inoperable, and 43 refused surgery. Forty-two patients had T1 tumors, and 38 had T2 tumors. RESULTS: The median follow-up period for living patients was 35.5 months. For all 80 patients, the 3-year overall survival, cause-specific survival, and local control rates were 75% (IA: 74%; IB: 76%), 86% (IA: 84%; IB: 88%), and 82% (IA: 87%; IB: 77%), respectively. There were no significant differences in treatment results among the 3 protocols. Grade 3 pulmonary toxicity was observed in only 1 patient. CONCLUSIONS: Proton therapy and carbon-ion therapy are safe and effective for stage I NSCLC. Further investigation of particle therapy for stage I NSCLC is warranted. Cancer 2010;116:2476-85.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Treatment Protocolsmentioning

confidence: 99%

See 1 more Smart Citation

High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancer

Iwata

Murakami

Demizu

et al. 2010

Cancer

Self Cite

100

View full text Add to dashboard Cite

show abstract

“…The majority of these studies conclude that late effects induced by protons or helium ions are nearly equivalent to what one would expect from equivalent photon doses. Proton RBE values are 1.0, except near the very end of the stopping Bragg peak [10,11,13,44,53,86,87] In conclusion, there is strong evidence supporting the use of proton radiotherapy as superior even to IMRT [40] and perhaps even as a replacement for external beam radiation therapy [106].…”

Section: Proton and Helium Radiation Therapymentioning

confidence: 99%

“…The Japanese program was a pioneer in the development of particle beam delivery gated to respiration. The Japanese program also uses RBE determinations from the laboratory, and modified by clinical judgement to implement their beam delivery [42,53,108].…”

Section: Carbon Ion Beam Radiation Therapymentioning

confidence: 99%

Late effects from hadron therapy

Blakely

Chang

2004

Radiotherapy and Oncology

View full text Add to dashboard Cite

Successful cancer patient survival and local tumor control from hadron radiotherapy warrant a discussion of potential secondary late effects from the radiation. The study of late-appearing clinical effects from particle beams of protons, carbon, or heavier ions is a relatively new field with few data. However, new clinical information is available from pioneer hadron radiotherapy programs in the USA, Japan, Germany and Switzerland. This paper will review available data on late tissue effects from particle radiation exposures, and discuss its importance to the future of hadron therapy.Potential late radiation effects are associated with irradiated normal tissue volumes at risk that in many cases can be reduced with hadron therapy. However, normal tissues present within hadron treatment volumes can demonstrate enhanced responses compared to conventional modes of therapy. Late endpoints of concern include induction of secondary cancers, cataract, fibrosis, neurodegeneration, vascular damage, and immunological, endocrine and hereditary effects. Low-dose tissue effects at tumor margins need further study, and there is need for more acute molecular studies underlying late effects of hadron therapy.2

show abstract

Structural Damage and Recrystallization Response of Garnet Crystals to Intense Electronic Excitation

Han

Zarkadoula

Crespillo

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

The susceptibility to irradiation-induced damage, the fundamental mechanism of the relaxation kinetics, and the corresponding recrystallization effect related to the cation radius ratio are comprehensively investigated for Y 3 Al 5 O 12 and Gd 3 Ga 5 O 12 garnet crystals under 645 MeV Xe 35+ irradiation with different fluences of 5 × 10 11 -3 × 10 12 ions cm −2 . Regarding different lattice distortion and swelling levels, the observed microstructure transformations to disordered and amorphous phases, and corresponding hillock dimensions, consistently confirm that Gd 3 Ga 5 O 12 has a higher susceptibility to radiation damage than Y 3 Al 5 O 12 . Combined with iTS model calculations, although Y 3 Al 5 O 12 has higher atomic temperature and energy deposition than Gd 3 Ga 5 O 12 under the same ion velocity and electronic energy loss, the relatively high thermal conductivity and specific heat coefficient of Y 3 Al 5 O 12 crystals enhance the conduction and dissipation of deposition energy, and Gd 3 Ga 5 O 12 , with a higher cation-radius-ratio (r A /r B ), is more easily damaged to amorphous phase due to the less favorable kinetics of ordering and recovery of a melted track region to the crystalline phase. Additionally, the significant bandgap modification in spectral ranges of 5.88-6.75 eV for Y 3 Al 5 O 12 and 4.83-5.41 eV for Gd 3 Ga 5 O 12 , and the enhancement of defect-assisted-related luminescence are achieved, providing a basis to design novel optoelectronic devices in microelectronics fields.

show abstract

Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center

Cited by 122 publications

References 14 publications

High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancer

High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancer

Late effects from hadron therapy

Structural Damage and Recrystallization Response of Garnet Crystals to Intense Electronic Excitation

Contact Info

Product

Resources

About